Landscape Capital Management L.L.C. Invests $4.35 Million in West Pharmaceutical Services, Inc. $WST

Landscape Capital Management L.L.C. purchased a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 12,112 shares of the medical instruments supplier’s stock, valued at approximately $4,348,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of West Pharmaceutical Services in the second quarter valued at about $2,387,990,000. State Street Corp boosted its holdings in West Pharmaceutical Services by 2.1% in the 2nd quarter. State Street Corp now owns 3,271,866 shares of the medical instruments supplier’s stock valued at $715,884,000 after purchasing an additional 68,330 shares during the period. Artisan Partners Limited Partnership grew its position in shares of West Pharmaceutical Services by 2.9% during the 4th quarter. Artisan Partners Limited Partnership now owns 2,850,401 shares of the medical instruments supplier’s stock worth $784,259,000 after purchasing an additional 79,481 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of West Pharmaceutical Services during the second quarter worth approximately $733,733,000. Finally, Generation Investment Management LLP acquired a new stake in shares of West Pharmaceutical Services in the second quarter valued at approximately $728,168,000. 93.90% of the stock is owned by institutional investors and hedge funds.

West Pharmaceutical Services Stock Performance

Shares of West Pharmaceutical Services stock opened at $352.94 on Friday. The company has a 50 day moving average of $348.61 and a 200-day moving average of $299.75. West Pharmaceutical Services, Inc. has a 1-year low of $223.83 and a 1-year high of $386.00. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. The company has a market cap of $24.84 billion, a PE ratio of 45.19, a price-to-earnings-growth ratio of 2.47 and a beta of 1.15.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The business had revenue of $872.30 million for the quarter, compared to analysts’ expectations of $839.98 million. During the same period last year, the firm posted $1.84 earnings per share. The firm’s quarterly revenue was up 13.8% compared to the same quarter last year. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, equities research analysts forecast that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th were given a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 0.2%. The ex-dividend date was Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio is currently 11.27%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on WST shares. Stephens reiterated an “overweight” rating and issued a $360.00 price target on shares of West Pharmaceutical Services in a research note on Tuesday, June 2nd. Evercore restated an “outperform” rating and set a $425.00 price objective on shares of West Pharmaceutical Services in a research note on Monday, July 27th. Wolfe Research started coverage on West Pharmaceutical Services in a report on Monday, June 1st. They issued an “outperform” rating and a $375.00 price objective for the company. TD Cowen reiterated a “buy” rating on shares of West Pharmaceutical Services in a research report on Wednesday, July 15th. Finally, Weiss Ratings raised West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, West Pharmaceutical Services presently has an average rating of “Moderate Buy” and a consensus target price of $368.08.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.